X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Pfizer with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PFIZER vs ALKEM LABORATORIES - Comparison Results

PFIZER    Change

Pfizer India is a 71% subsidiary of the world's largest pharmaceuticals company Pfizer Inc. Pfizer derives a larger share of its revenues from the pharmaceuticals division (81%). The company also has presence in the animal health (13%) and clinical d... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PFIZER ALKEM LABORATORIES PFIZER/
ALKEM LABORATORIES
 
P/E (TTM) x 30.6 - - View Chart
P/BV x 5.2 6.7 78.1% View Chart
Dividend Yield % 0.6 0.7 95.8%  

Financials

 PFIZER   ALKEM LABORATORIES
EQUITY SHARE DATA
    PFIZER
Mar-16
ALKEM LABORATORIES
Mar-16
PFIZER/
ALKEM LABORATORIES
5-Yr Chart
Click to enlarge
High Rs2,7241,589 171.4%   
Low Rs1,6111,232 130.8%   
Sales per share (Unadj.) Rs440.9417.5 105.6%  
Earnings per share (Unadj.) Rs48.756.3 86.5%  
Cash flow per share (Unadj.) Rs75.864.7 117.1%  
Dividends per share (Unadj.) Rs15.0012.70 118.1%  
Dividend yield (eoy) %0.70.9 76.9%  
Book value per share (Unadj.) Rs462.9292.9 158.0%  
Shares outstanding (eoy) m45.75119.57 38.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.93.4 145.5%   
Avg P/E ratio x44.525.1 177.7%  
P/CF ratio (eoy) x28.621.8 131.2%  
Price / Book Value ratio x4.74.8 97.2%  
Dividend payout %30.822.6 136.5%   
Avg Mkt Cap Rs m99,163168,653 58.8%   
No. of employees `0002.9NA-   
Total wages/salary Rs m2,7589,171 30.1%   
Avg. sales/employee Rs Th6,981.7NM-  
Avg. wages/employee Rs Th954.5NM-  
Avg. net profit/employee Rs Th771.1NM-  
INCOME DATA
Net Sales Rs m20,17049,915 40.4%  
Other income Rs m8571,645 52.1%   
Total revenues Rs m21,02851,561 40.8%   
Gross profit Rs m4,3108,482 50.8%  
Depreciation Rs m1,2391,006 123.2%   
Interest Rs m5671 0.8%   
Profit before tax Rs m3,9238,451 46.4%   
Minority Interest Rs m0-114 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m990-   
Tax Rs m1,7941,606 111.7%   
Profit after tax Rs m2,2286,731 33.1%  
Gross profit margin %21.417.0 125.7%  
Effective tax rate %45.719.0 240.7%   
Net profit margin %11.013.5 81.9%  
BALANCE SHEET DATA
Current assets Rs m16,29927,062 60.2%   
Current liabilities Rs m7,59415,324 49.6%   
Net working cap to sales %43.223.5 183.5%  
Current ratio x2.11.8 121.5%  
Inventory Days Days6567 98.1%  
Debtors Days Days2641 62.4%  
Net fixed assets Rs m8,62212,610 68.4%   
Share capital Rs m458239 191.3%   
"Free" reserves Rs m20,72234,490 60.1%   
Net worth Rs m21,18035,027 60.5%   
Long term debt Rs m251,212 2.1%   
Total assets Rs m29,13754,387 53.6%  
Interest coverage x755.513.6 5,554.1%   
Debt to equity ratio x00 3.4%  
Sales to assets ratio x0.70.9 75.4%   
Return on assets %7.713.6 56.3%  
Return on equity %10.519.2 54.7%  
Return on capital %19.024.9 76.4%  
Exports to sales %0.112.9 0.5%   
Imports to sales %17.53.1 566.5%   
Exports (fob) Rs m126,461 0.2%   
Imports (cif) Rs m3,5261,540 228.9%   
Fx inflow Rs m526,563 0.8%   
Fx outflow Rs m1403,012 4.6%   
Net fx Rs m-883,552 -2.5%   
CASH FLOW
From Operations Rs m3,4367,259 47.3%  
From Investments Rs m-6,9911,864 -375.0%  
From Financial Activity Rs m-619-9,273 6.7%  
Net Cashflow Rs m-4,174-150 2,782.3%  

Share Holding

Indian Promoters % 0.0 66.9 -  
Foreign collaborators % 63.9 0.0 -  
Indian inst/Mut Fund % 7.5 33.1 22.7%  
FIIs % 4.9 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 23.7 0.0 -  
Shareholders   85,207 68,381 124.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PFIZER With:   ASTRAZENECA PHARMA  PANACEA BIOTECH  CADILA HEALTHCARE  GSK PHARMA  PLETHICO PHARMA  

Compare PFIZER With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 262 Points Up; ONGC & Tata Steel Top Gainers(Closing)

Indian share markets ended the day on a strong note. At the closing bell, the BSE Sensex finished higher by 262 points. While, the NSE Nifty finished up by 91 points.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Beware the 5th year of the Modi Regime(The Honest Truth)

May 22, 2018

2017 was a great year for the market. You were rewarded for taking excessive risk. But Ajit Dayal believes 2018 will be different. You will be rewarded for doing the opposite. Read on to know more...

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PFIZER SHARE PRICE


May 25, 2018 (Close)

TRACK PFIZER

PFIZER - UNICHEM LAB COMPARISON

COMPARE PFIZER WITH

MARKET STATS